home / stock / nrx:cc / nrx:cc news

NRX:CC News and Press, NurExone Biologic Inc. From 11/23/23

Stock Information
Company Name: NurExone Biologic Inc.
Stock Symbol: NRX:CC
Market: TSXVC
Website: nurexone.com
Menu
NRX:CC NRX:CC Quote NRX:CC Short NRX:CC News NRX:CC Articles NRX:CC Message Board
Get NRX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NRX:CC - Expected earnings - NurExone Biologic Inc.

NurExone Biologic Inc. (NRX:CA) is expected to report $-0.03 for Q3 2023
NRX:CC - Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

2023-11-07 16:00:06 ET There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36% after the announc...

NRX:CC - When Technicals and Fundamentals Converge, A Nice Uptrend Ensues

2023-10-31 15:57:33 ET Some investors only pay attention to fundamentals. Others put more weight on technical charts. Another way of looking at it is to think of technical as being useful for quick decisions for those good at technical analysis, while fundamentals can be beneficial for a de...

NRX:CC - Shares Up Following Orphan Drug Designation

2023-10-30 13:16:23 ET Classification as an %OrphanDrug incentivizes and supports the development of certain treatments, increasing access to therapies for rare diseases and providing significant benefits, including market exclusivity, regulatory assistance and financial incentives. ...
NRX:CC - NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Or...

NRX:CC - Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee

TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with t...

NRX:CC - NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

TORONTO and HAIFA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy (“ ExoTherapy ”) f...
NRX:CC - NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum

TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with t...

NRX:CC - 24 Cent Micro Cap May Hold The Key To Potential Breakthrough In Acute Spinal Cord Injury

2023-10-04 16:06:31 ET An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined to a wheelchair. What if there were a way to repair the dam...

NRX:CC - NurExone Appoints Dr. Reuter Investor Relations in Europe

TORONTO and HAIFA, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal ...
Previous 10 Next 10